The trial consists of 3 consecutive periods: a screening period of up to 48 hours, a 2-week IMP treatment period and a follow-up period of up to 7 weeks after last IMP intake.~All subjects will undergo a series of efficacy, safety, and laboratory assessments. Safety laboratory tests and samples for future exploratory analysis will be obtained at the screening visit.~The trial duration for an individual subject will not exceed 9 weeks.
This trial is a randomized, double-blind, placebo-controlled, parallel-group, 2-arm, multicenter trial to evaluate the efficacy and safety of C21 versus placebo as add on to SoC in adult subjects with COVID-19.~The trial will enroll a total of maximum 300 randomized subjects, 150 per arm (oral C21 100 mg twice a day (b.i.d.) or placebo for 14 days) according to the 1:1 randomization.